Skip to main content

Cotempla XR-ODT

Generic name: methylphenidate
Dosage form: extended-release orally disintegrating tablet
Drug class: CNS stimulants

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 4, 2023.

What is Cotempla XR-ODT?

Cotempla XR-ODT is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) in children. It contains a central nervous system (CNS) stimulant called methylphenidate.

Cotempla XR-ODT is a grape-flavored tablet that is taken in the morning and is marketed as an "on the go" medication that dissolves in the mouth and works quickly.

Exactly how Cotempla XR-ODT works in children with ADHD is not known. However, people with ADHD have been found to have low levels of dopamine and noradrenaline, which are two neurotransmitters (chemical messengers) found in the brain. Cotempla XR-ODT boosts the levels of these neurotransmitters by preventing their re-uptake from the space between nerve cells (neurons) in the brain. It increases activity in the brain, especially in the areas that help regulate behavior and attention.

Medications containing methylphenidate, such as Cotempla XR-ODT, are schedule II federally controlled substances because they can be a target for people who abuse prescription medicines or street drugs. Selling or giving away Cotempla XR-ODT may harm others, and is against the law.

Cotempla XR-ODT was approved for use by the US Food and Drug Administration (FDA) in 2017, although methylphenidate in another formulation was first approved many years earlier in 1955.

What is Cotempla XR-ODT used for?

Cotempla XR-ODT is a prescription medicine used for the treatment of ADHD in children from 6 to 17 years of age. It may help increase attention and decrease impulsiveness and hyperactivity.

It is not known if it is safe and effective in children under 6 years of age.

Important information

Cotempla XR-ODT can cause serious side effects, including:

Who should not take Cotempla XR-ODT?

Do not give Cotempla XR-ODT if your child if they are:

What should I tell my doctor before taking Cotempla XR-ODT?

Before taking Cotempla XR-ODT, tell your child's healthcare provider about all medical conditions, including if your child:

How should I take Cotempla XR-ODT?

Your healthcare provider may sometimes stop your child's treatment with this medication for a while to check ADHD symptoms.

What happens if I miss a dose?

If a dose of Cotempla XR-ODT is missed, it should be taken as soon as you remember. If it is near bedtime or near the time of the next dose then skip the missed dose and take the next dose at the regular time. Do not take a double dose.

What happens if I overdose?

If too much Cotempla XR-ODT is taken, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking Cotempla XR-ODT?

Avoid drinking alcohol during treatment with Cotempla XR-ODT.

Dosing information

The recommended starting dose for Cotempla XR-ODT for patients 6 to 17 years of age is 17.3 mg given orally once daily in the morning. The dosage may be increased weekly in increments of 8.6 mg to 17.3 mg per day. Daily dosage above 51.8 mg is not recommended.

What are the side effects of Cotempla XR-ODT?

Cotempla XR-ODT can cause serious side effects, including:

The most common side effects of methylphenidate products include:

These are not all the possible side effects of this medication.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Interactions

Tell your healthcare provider about all of the medicines that your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Cotempla XR-ODT and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted during treatment.

Your healthcare provider will decide whether Cotempla XR-ODT can be taken with other medicines.

Especially tell your healthcare provider if your child takes medicine to treat depression, including MAOIs.

Know the medicines that your child takes. Keep a list of the medicines with you to show your healthcare provider and pharmacist when your child get a new medicine.

Do not start any new medicine during treatment without talking to your healthcare provider first.

Pregnancy and breastfeeding

Tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known whether Cotempla XR-ODT will harm your unborn baby.

There is a pregnancy registry for females who are exposed to this medication during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Cotempla XR-ODT and their baby. If your child becomes pregnant during treatment, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants. You can register by calling 1-866-961-2388.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. Cotempla XR-ODT passes into breast milk. You and your healthcare provider should decide if your child will take Cotempla XR-ODT or breastfeed..

Storage

Keep out of the reach of children.

What are the ingredients in Cotempla XR-ODT?

Active Ingredient: Methylphenidate

Inactive Ingredients: Mannitol, Fructose, Microcrystalline Cellulose, Crospovidone, Methacrylic Acid, Polystyrene Sulfonate, Citric Acid, Colloidal Silicon Dioxide, Grape Flavor, Natural Masking Type Powder, Triethyl Citrate, Magnesium Stearate, Ethylcellulose, Sucralose, Lake Blend Purple, and Polyethylene Glycol

Cotempla XR-ODT is manufactured for Neos Therapeutics Brands, LLC, Grand Prairie, TX 75050

Popular FAQ

Metilfenidato is the Spanish, Italian, and Portuguese translation for methylphenidate which may be used to treat children or adults with attention deficit hyperactivity disorder (ADHD) to help with hyperactivity and impulsive behavior, and allow them to concentrate better. Metilfenidato may also be used to treat adults with narcolepsy. Metilfenidato translates to methylphenidate. Continue reading

More FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.